ALPHAMAB ONCOLO.DL-000002 (3NK) - Total Assets
Based on the latest financial reports, ALPHAMAB ONCOLO.DL-000002 (3NK) holds total assets worth €2.10 Billion EUR (≈ $2.45 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of ALPHAMAB ONCOLO.DL-000002 to assess the company's total reinvestment commitment from operating cash flow.
ALPHAMAB ONCOLO.DL-000002 - Total Assets Trend (2021–2025)
This chart illustrates how ALPHAMAB ONCOLO.DL-000002's total assets have evolved over time, based on quarterly financial data. Check 3NK cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
ALPHAMAB ONCOLO.DL-000002 - Asset Composition Analysis
Current Asset Composition (December 2025)
ALPHAMAB ONCOLO.DL-000002's total assets of €2.10 Billion consist of 76.0% current assets and 24.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 12.3% |
| Accounts Receivable | €61.95 Million | 3.0% |
| Inventory | €107.88 Million | 5.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €19.70 Million | 0.9% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how ALPHAMAB ONCOLO.DL-000002's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 3NK market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ALPHAMAB ONCOLO.DL-000002's current assets represent 76.0% of total assets in 2025, a decrease from 78.2% in 2021.
- Cash Position: Cash and equivalents constituted 12.3% of total assets in 2025, down from 29.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 5.1% of total assets.
ALPHAMAB ONCOLO.DL-000002 Competitors by Total Assets
Key competitors of ALPHAMAB ONCOLO.DL-000002 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
ALPHAMAB ONCOLO.DL-000002 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.67 | 6.74 | 4.61 |
| Quick Ratio | 5.29 | 6.41 | 4.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.31 Billion | €1.46 Billion | €1.25 Billion |
ALPHAMAB ONCOLO.DL-000002 - Advanced Valuation Insights
This section examines the relationship between ALPHAMAB ONCOLO.DL-000002's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.88 |
| Latest Market Cap to Assets Ratio | 0.41 |
| Asset Growth Rate (YoY) | -6.5% |
| Total Assets | €2.10 Billion |
| Market Capitalization | $866.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values ALPHAMAB ONCOLO.DL-000002's assets below their book value (0.41x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ALPHAMAB ONCOLO.DL-000002's assets decreased by 6.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ALPHAMAB ONCOLO.DL-000002 (2021–2025)
The table below shows the annual total assets of ALPHAMAB ONCOLO.DL-000002 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.10 Billion ≈ $2.45 Billion |
-6.45% |
| 2024-12-31 | €2.24 Billion ≈ $2.62 Billion |
+4.90% |
| 2023-12-31 | €2.14 Billion ≈ $2.50 Billion |
+0.92% |
| 2022-12-31 | €2.12 Billion ≈ $2.48 Billion |
-21.72% |
| 2021-12-31 | €2.71 Billion ≈ $3.16 Billion |
-- |
About ALPHAMAB ONCOLO.DL-000002
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors… Read more